Femara patent

Femara patent

Posted: 145 Date: 09-Dec-2017
Patent US4978672 - Alpha-heterocyclc substituted tolunitriles.

Patent US4978672 - Alpha-heterocyclc substituted tolunitriles.

Dec 18, 1990. The invention is concerned with aromatase inhibiting compounds of formula I ##STR1## wherein R and Ro represent hydrogen or lower alkyl;. Aug 4, 2010. The present invention relates to an improved process for preparation of the non-steroidal aromatase inhibitor drug, Letrozole of formula I and. Here we report the synthesis of carbon-11 labeled letrozole and its assessment as a. This was a modification of the literature and patent procedures 14, 16.

Synthesis and PET studies of 11C-cyanoletrozole Femara®, an.

Synthesis and PET studies of 11C-cyanoletrozole Femara®, an.

Peter MacDonald, Ettore Bigatti, Pierluigi Rossetto, Zvi Harel, "Process for the preparation of letrozole." U. S. Patent US20070066831, issued March 22, 2007. Sep 2, 2009. Femara. Novartis. Letrozole. 06/11. X. Breast cancer. Mirapex. Boehringer Ingelheim. Pramipexole. 03/11. X. Restless leg syndrome. Cosopt.

Patent US7538230 - Letrozole production process - Google Patents
Patent US7538230 - Letrozole production process - Google Patents

May 26, 2009. Provided is a method for preparing letrozole, which includes reacting an activated bis-4-cyanophenyl-methane with a triazole to produce. Dec 4, 2008. 4,978,672, listed in the Orange Book for Novartis' Femara® tablet NDA. The patent claims are drawn to the active pharmaceutical ingredient in.

Femara patent
Rating 4,4 stars - 531 reviews